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Oral Presentations S179of immunotherapy treatment. B7-H1 antibody administration
significantly improved long-term survival after immunotherapy
(40% vs 0% for controls), indicating that the B7-H1/PD-1
pathway inhibits development of myeloma-specific immunity. We
are addressing that possibility that other immune suppressive
mechanisms can be targeted to further improve immunotherapy
efficacy, and several candidates have been identified including
CD41Foxp31 regulatory T cells. These results support the use of
B7-H1/PD-1 blocking strategies to increase tumor immunity in
myeloma patients.70
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While adoptive transfer of cytotoxic T lymphocytes (CTLs) en-
grafted with chimeric antigen receptors (CARs) has produced objec-
tive clinical responses in vivo, the infused cells usually fail to persist
long-term, limiting benefit. We have recently demonstrated that
CTL persistence can be improved by engineering cells to express
the IL7 receptor alpha chain (IL7Ra) which is physiologically absent
on CTLs, followed by infusion of IL7 cytokine. However, this ap-
proach requires access to clinical grade cytokine, and biodistribution
of cytokine at tumor sites may be insufficient. To circumvent these
problems we have prepared two CTL products; one expressing a tu-
mor-specific CAR in combination with IL7Ra (product #1), and
a second engineered to co-express the same CAR and produce IL7
cytokine (product #2). In this way both products have anti-tumor ac-
tivity, mediated through the CAR, while cytokine produced from
CTL#2 should support the survival and persistence of CTL#1 ex-
pressing the IL7Ra. A binary system such as this should be intrinsi-
cally safer than incorporating a positive feedback loop of both
cytokine and receptor in a single cell.
As proof of principal we used the SFG-CAR that targets the kappa
light chain, expressed on B cell malignancies. We made two retrovi-
ral vectors, SFG-CAR/IL7Ra-GFP (#1) and SFG-CAR/IL7cyto-
mOrange (#2) and transduced EBV-CTL from 3 donors with each
vector. FACS analysis indicated that all the transgenes were ex-
pressed at approx. equivalent levels; CTL#1 (CAR, IL7Ra andPatient
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median 1 18 22GFP; 58%615, 53%618, 57.8%612) and CTL#2 (CAR and mOr-
ange; 54%618 and 52%620). The modified CTL were functional,
and cells transduced with either vector were able to kill the Kappa1
B cell tumor Daudi in Cr51 assay (72%613 and 69%625, respec-
tively) at an R:S of 40:1. We confrmed the function of IL7Ra (#1)
by measuring pSTAT5 and cell proliferation after IL7 administra-
tion (67,64862703 CPM vs 8,7646793 CPM when cells were cul-
tured in media). In addition, we were able to measure IL7 cytokine
from product #2 by ELISA. IL7 production was dependent on the
intensity of antigenic stimulation as demonstrated using different ra-
tios of CTL:EBV-LCLs (4:1, 2:1, 1:1 and 1:2 which induced 3.7, 20,
99, and 192pg/ml IL7, respectively). Finally to demonstrate that
product #1 could sustain #2, we mixed the cultures at a 1:4 ratio.
Over 3 weeks, CTL#1 progressively increased (14% to 87%), while
the frequency of CTL#2 progressively declined over the same period
(63% to 5%).71
HIGH-YIELD OF CD341 CELLS WITH BORTEZOMIB-BASED MOBILIZA-
TION REGIMEN IS ASSOCIATED WITH SPECIFIC GENOMIC EXPRESSION
PATTERNS, DECREASE IN SDF-1 PLASMA LEVELS AND UP-REGULATION
OF CXCR4 IN MULTIPLE MYELOMA (MM) PATIENTS
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Typical stem cell mobilization regimens in MM include G-CSF
alone or in combination with plerixafor or high-dose cyclophospha-
mide (CTX). Given the known in vitro/in vivo synergy between borte-
zomib (VELCADE, Vel) and alkylating agents, we investigated the
potential for concurrent cytoreduction by adding Vel to the mobiliza-
tion regimen. Eligible patients (pts) had symptomatic, Durie-Salmon
stage II/III MM. All pts received six 21-day cycles of Vel/dexametha-
sone6 liposomal doxorubicin. Cycle 7 only, mobilization (Vel-mob)
comprised Vel 1.3 mg/m2 on days 1, 4, 8, and 11, CTX 3 g/m2 on
day 8, and Filgrastim 10 ug/kg (rhG-CSF) for 10 days from day 9. At
data cut-off, 25pts havebeenmobilized. In comparison topts receiving
just G-CSF alone, there was a significant increase in the median
CD341 collection (22.6106/kgvs10.6106/kg). Inaddition, thenum-
ber of CD341 cells/kg collected far exceeded the study goal of
10X106cells/kg which is typical of using CTX and/or GCSF alone inStem Cells
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